 |
July 4th, 2003, 10:47
|
|
Administrator
|
|
Join Date: 2001
Posts: 1,085
|
|
|
PET Finds Unexpected Metastatic Disease in Approx. 15% of NSC Lung Cancer Patients
TITLE: Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer
REF: Ann Thorac Surg 1999;67:790-797. http://ats.ctsnetjournals.org/cgi/c...stract/67/3/790
STUDY TYPE: prospective trial with a follow-up period of approx. 1.5 years
PATIENTS: 97 patients under surgical consideration for the treatment of NSC lung cancer
FINDINGS: Sens & spec for N2 and N3 mediastinal disease was 72% and 97% using PET, compared to 20% and 90% for CT. PET correctly identified unexpected distant metastatic disease in 16.5% and correctly altered the stage of the cancer in 26.8%. PET altered management in 37% of patients.
CONCLUSION: The addition of PET imaging has a significant clinical impact upon NSCLC patients being considered for surgery
COMMENT: some physicians (particularly nuclear medicine docs) believe that all NSCLC patients should receive a PET scan prior to surgery |
| Thread Tools |
Search this Thread |
|
|
|
| Display Modes |
 Linear Mode
|
Posting Rules
|
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is On
|
|
|
All times are GMT -8. The time now is 03:22.
|
